Lead time is the measured gap between a first qualifying positive blood sample and a later clinical event. It depends on who is counted and when tests were done, and it is not extra life.
In a ctDNA monitoring study, lead time is the date of a defined later event, such as confirmed clinical recurrence, minus the date of the first qualifying positive blood sample. The definition needs rules: whether recurrence means imaging, pathology or symptoms, whether the blood date is collection or reporting, whether a positive result triggered an extra scan, and whether treatment began on the signal. Blood draws and scans are both intermittent, so the observed gap reflects both schedules. A negative draw at month 3 and a first positive at month 6 do not locate when the signal began.
The denominator matters as much as the number. A median taken only over people with both an earlier positive and a later recurrence describes that selected group. It leaves out recurrences with no earlier positive, and people who are positive but have not recurred at the data cutoff have unfinished intervals, which are censored rather than zero or infinite. In García-Murillas and colleagues' prospective breast-cancer study, with blood taken every 3 months in the first year and every 6 months after, ctDNA detection preceded clinical relapse by a median of 10.7 months (95% CI 8.1 to 19.1) in the combined cohort of 144, and ctDNA found distant extracranial relapse in 22 of 23 patients but brain-only relapse in 1 of 6. In the c-TRAK TN trial, ctDNA was detected in 27.3% by 12 months and 7 patients relapsed without prior detection. A longer lead time shows earlier detection. It does not show that acting on the signal helps people live longer, which is the separate lead-time bias problem.
Showing the technology this term belongs to: Liquid biopsy (ctDNA).
The first prospective test of acting on ctDNA in triple-negative disease, and a negative one: with a quarterly, single-mutation assay the window between detectable DNA and visible metastasis was too short to intervene. Later designs use tumour-informed assays, earlier sampling and drugs with more single-agent activity.
For TNBC, where brain metastases are common, the blind spot matters: a negative ctDNA test does not exclude intracranial relapse.
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA) and the tags biomarker, measurement.
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA) and the tags biomarker, measurement.
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Continuous and near-continuous ctDNA monitoring, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA), Triple-negative breast cancer (TNBC).
Shares Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/